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Summary: The competitive binding of human arantitrypsin and human a2-macroglobulin to porcine pan-
creatic elastase was studied. Mixtures of these two protease inhibitors, when titrated against elastase give
Inhibition curves analogous to those obtained with human plasma. This is however not the case when the
individual inhibitors are used. A theoretical treatment enabled us to devise an assay method to determine
the amounts of functional activity of arprotease inhibitor and a2-macroglobulin respectively in human
plasma.
Introduction
Since the first observations of antiproteolytic activity
in blood in 1897 (1) at least nine protease inhibitors
have been identified. The two major inhibitors are cti-
aütitrypsin (now usually called c^-protease inhibitor)
and a2-macrpglobulin, which represent about 70% of
the plasma protease inhibitor activity by weight, and
probably all the antirelastase activity (2). Although
both arprotease inhibitor and c^macroglobulin re-
act with elastase, they do so in different ways. The
former completely inhibits human neutrophil elastase
using elastin äs Substrate, whereas a2-macroglobulin
only partly inhibits this System (3).
The relationship between j-protease inhibitor defl·
ciency and early onset of emphysema in individuals
with genetic deficiency^ äs well äs in smokers is well
documented (4, 5). The di-protease inhibitor inhibits
both the proteolytic and the amidolytic activity (on
synthetic Substrates) of plasma proteases by binding
to them and blocking their active sites (6). The com^
plex formed is very stable and does not dissociate
even in the presence of other binders such äs <x2-
macroglobulia (7).
The a2-macroglobulin present in human plasma binds
to all four classes of endopeptidases (8). On binding,
the a2-macroglobulin molecule undergoes a confor-
mational change which entraps the enzyme. In this
way Inhibition does not involve interaction with the
active site of the protease, and the bound enzyme
still possesses activity toward low molecular weight
Substrates (9) but decreased activity toward native
proteins (10). Consequently, when low molecular
weight synthetic Substrates are used for measuring the
protease inhibitory capacity of plasma, the protease
bound to arprotease inhibitor will be completely
inhibited. Ön the other hand, reaction with <x2-macro-
globülin may cause only slight Inhibition of protease,
or increased activity may even be found. When neu-
trophil elastase becomes complexed with a2-macro-
globulin, its activity increases 15 to 16 times com-
pared with that of the free enzyme (9).
It has thus become clear that variable concentrations
of a2-macroglobülin in plasma may modulate signifi-
cantly the inhibitory role of aj-protease inhibitor in
human plasma. In vivo, a balance is necessary in the
synthesis and breakdown of elastin. It is possible that
this homeostasis can be disturbed either by inactiva-
tiön of cti-protease inhibitor by such factors äs smok-
ing (11), or by changes in the activity of <x2-macroglo-
bulin. In the latter case it is important to determine
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the level of a2-macroglobulin that can aotively bind
protease, rather than the immunologically determined
level. Several colorimetric methods have been devel-
oped to measure a2-macroglobulin in human blood,
based on the ability of a2-macroglobulin protease
complex to hydrolyse a low molecular weight syn-
thetic Substrate in the presence of excess protease
inhibitor.
Ganrot (12) used trypsin s the protease, benzoyl D,L-
arginine-p-nitroanilide s the Substrate and soybean
trypsin inhibitor to block excess trypsin. More re-
cently Cullmann & Dick (13) described a similar
method using carbobenzoxy-Val-Gly-Arg-/?-nitroan-
ilide s Substrate and aprotinin s the inhibitor; and
Rao et al. (14) used a crude preparation of redwood
seed extract (Adenanthera pavonia) s the source of
inhibitor. None of these methods takes into account
the endogenous serum arprotease inhibitor in the
final calculation of the amount of a2-macroglobulin.
In this report, .we describe the competitive binding of
arprotease inhibitor and a2-macroglobulin to por-
cine pancreatic elastase. The results are used to gener-
ate a method for assaying the amounts of functional
activity of the two binders in human plasma.
Materials and Methods
Human a2-macroglobulin (90% pure), human α,-protease in-
hibitor and succinyltrialanyl-p-nitroanilide were obtained from
Hoechst. Porcine pancreatic elastase (EC 3.4.21.11) was ob-
tained from Boehringer, Mannheim.
Based on the manufacturer's specifications of 70 U/mg and the
rate constant of 73 s~! quoted by Beith et al. (15), this elastase
is 40% pure.
Fresh human blood (10 ml) was drawn from a non-smoking
volunteer into a lithium heparin Venoject tube. The buffer used
for all assays was 0.1 mol/1 Tris-HCl pH 7.4. All chemicais used
were of analytical grade (Merck).
Assumed molecular masses were:
Porcine pancreatic elastase: Mr = 25 000;
α,-protease inhibitor: Afr = 54000;
a2-macroglobulin: MT = 725000.
Theoretical model
Consider three simultaneous reactions (α,ΡΙ
inhibitor, and a2-M = a2-macroglobulin):
+ a, PI
(a - x)
Elastase + α2 Μ
(c - χ - y (b - y

















a, b, and c are the initial numbers of molecules of α,ΡΙ, α2Μ,
and elastase, respectively; and
χ is the number of molecules of the complex formed with α,ΡΙ,
while
y and z represent the numbers of molecules of the binary and
ternary complexes respectively betweeri a2M and elastase at
any stage of the reaction.
When a -h 2b > c
Here the competition between the two binders depends on the
rate constants k, and k2, aecording to the following equation.
ki _ log (a - x)/a
1b~ ~ log (b -~ y - z)/b
log (a - x)/a
log Xo
where Xo is the mol fraction of armacroglobulin unbound (16,
17). However, the bound fraction of the a2-macroglobulin will
be distributed between binary and ternary complex, and.the
amounts of each will depend on the amount of enzyme left at
any particular time (16), taking into account the amount of a^
protease inhibitor and the rate of its binding to enzyme. Hence
there is no simple relationship. However, since k2 is greater
than k, (17, 18), the relative amount of enzyme bound to a2-
macroglobulin will increase s the total amount pf added mix-
ture of the 2 binders is increased. Hence we expect to find an
increase in enzyme catalytic activity s the volume, V, increases
beyond the equivalence point, Ve. This accounts for the increase
in catalytic activity after reaching a minimum in figure 1. How-
ever, even if the volume added is increased to extremes, the
maximum value attainable for the catalytic activity of the
complexes is f2D0.
D0 = Absorbance produced by the elastase with no
plasma added.
f2 = factor by which the catalytic activity of elastase
is changed when it becomes complexed with a2-
macroglobulin in the presence f excess a,-pro-
tease inhibitor.
When a + 2b < c
Since we allow sufficient time for the reaction to proceed to
completion, all a and b are bound to enzyme. Also, all the
a2-macroglobulin binds 2 elastase molecules per molecule ar
macroglobulin (16).
Hence, unreacted enzyme = c — a — 2b
The observed catalytic activity for a volume, V, f mix-
ture = Dv
Dv = K(c - a - 2b(l - f,))t! ... l,
where f, is the factor by which complexing of the enzyme with
a2-macroglobulm decreases (or increases) its catalytic activity.
When plasma is titrated against porcine pancreatic elastase, the
amounts of α,-protease inhibitor and a2-macroglobulin are in
a constant ratio to each other in the plasma.
Thus,
where a = AV and b = BV,
V = volume of plasma added
A == molar concentration of a, ̂ protease in-
hibitor in the plasma
B = molar concentration ofarmacroglobu-
lin in the plasma
t, and t2 = incubation times
K = a constant such that D0 = K c t2
D0 = absorbance produced by tfae elastase
with no plasma £dded
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therefore Determination off2K(c - AV - 2BV(1 -
c Λ _ Pv · t2\ _ 2B — Π 2 Since a2-macroglobulin bound to elastase cannot be detached
V \ Do · ti/ by arprotease inhibitor, f2 is determined by first saturating the
This is a linear relationship in V if ΙΊ is constant. However, it
contains 3 unknowns. Hence at least two of these must be
determined experimentally.
elastase with a2-macroglobulin and then adding an excess of
at-protease inhibitor after binding to a2-macroglobulin is com-
plete.
Methods
Assay ofinhibitory capacity ofplasma towards porcine pancrea c
elastase (flg. 1)
To (3 - x) ml of 0.1 mol/1 Tris-HCl buffer, 0.2 ml diluted
elastase Suspension (270 pmol) was added. Various amounts of
plasma (x ml) were added and incubated for 10 min at 37 °C.
Fifty μΐ of succinyl-trialanyl-/?-nitroanilide (40 g/l) were then
added and incubated for 20 min at 37 °C. The reaction was
stopped with 0.5 ml 100 g/l citric acid. Absorbance was read
at 410nm.
Titration of arprotease inhibitor against elastase (flg. 1)
Various volumes of arprotease inhibitor (8.9 mol/1) in buffer
were added to 0.2 ml of diluted elastase Suspension (267 pmol
per assay), and buffer added to a final volume of 3.2 ml. The
residual elastase activity was measured s described above for
plasma.
Titration of armacroglobulin against elastase (fig. 1)
Various volumes of an a2-macroglobulin solution (417 nmol/1)
were reacted for 5min at 37 °C with 1.6 nmol of porcine
pancreatic elastase in Tris-bufYer of pH 7.4. The unreacted
elastase was then neutralized with a large excess arprotease
inhibitor (10 nmol) by reaction for a further 5 minutes at 37 °C.
The volume of reaction mixture at this stage was 3.2 ml. Then
50 μΐ of succinyl-trialanyl-/j-nitroanilide (40 g/l) was added and
incubated for 20 min at 37 °C. The reaction was stopped with
0.5 ml of citric acid solution (100 g/l). Absorbance was read at
410nm.
Titration ofmixtures of arprotease inhibitor and oLi-
lin against elastase (fig. 2)
The concentrations of arprotease inhibitor and a2-macroglobu-
lia in the mixtures are shown in the legend t figure 2. The
assay was perfprmed s above, using 267 pmol of porcine
pancreatic elastase.
Titration of elastase against a mixture ofboth inhibitor s (excess
arprotease inhibitor added before measuring elastase activity)
. 3)
A fixed amount of elastase (267 pmol per assay) was added to
varying amounts of a mixture containing 7.5 μπιοΐ/ΐ of a2-
macroglobulin and 2.34 umol/1 of arprotease inhibitor (0 to
100 μ!) in a total volume of 3.2 ml Tris^buffer at pH 7.4. After
5 min reaction at 37 °C the unbound elast se was neutralized
by adding 10 ul of α! -pro tease Inhibitor (57 μοιρί/ϊ). Then 5 min
later 50 μΐ of enzyme Substrate (40 g/l) was added and allowed
to react for 20 min at 37 °C. The enzyme reaction was stopped
with 0.5 ml of citric acid (100 g/l) and absorbance read at
410nm.
Determination off\
The value of f\ can be determined by measuring the catalytic
activity of a known amount of enzyme alone and after adding
an excess of a2-macroglobulin. The binary and ternary com-
plexes have been shown to be equivalent, i. e. the two binding
sites on a2-macroglobulin are identical (19). Hence the question
of which complex is formed when measuring fj is irrelevant.
Results and Discussion
As shown in table l the values obtained for fi and f2
were:
f, = 0.74 and f2 = 0.70 at pH 7.4
These values are strongly dependent on the pH. How-
•ever, since the pH Optimum for the complex between
a2-macroglobulin and porcine pancreatic elastase is
7.4, all the assays were performed at this pH. Great
care must be taken to adjust the pH exactly in order
to obtain the above values for fi and f2.
Tab. l. The effect of inhibitors on porcine pancreatic elastase
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When normal human plasma was titrated against
fixed amounts of elastase, a complex curve was ob-
tained (fig. 1), which has been ascribed by Meyer et
al. (7) to the two main competing inhibitors in
plasma, viz: arprotease inhibitor and <x2-macroglobu-
lin.
The complex of a2-macroglobulin with porcine pan-
creatic elastase at pH 7.4 is at least 70% s catalytic-
ally active s the unbound elastase (tab. 1). The
individual effects of each of these inhibitors on elas-
tase, are shown in figure 1. For aj-protease inhibitor
the residual catalytic activity of the elastase was meas-
ured after the binding reaction was complete. A linear
regression with negative slope was obtained. This was
similar to the first half of the curve for plasma and
indicated that arprotease inhibitor is probably the
main factor responsible for the Inhibition observed
in plasma.
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^-Mocroglobulin solution [μΐ]
60 80 100 120 140 160 180 200 220 240 260
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·—·&!-Protease inhibitor solution [μΐ]
Fig. l. Titration of enzyme catalytic activity using 267 pmol
porcine pancreatic elastase against
a) (o—o) normal plasma and
b) (o —o) dj-protease inhibitor (8.9 μπιοΐ/ΐ).
Also titration of 1.6 nmol porcine pancreatic elastase
against a2-macroglobulin (417 nmol/1) after neutraliza-
tion of excess elastase with o^-protease inhibitor
(Δ — Δ) is shown (See Methods).
For the titration of a2-macroglobulin, we first allowed
the binding of elastase to proceed to completion,
then neutralized the excess elastase with fy-protease
inhibitor, before adding Substrate (see methods sec-
tion). The catalytic activity therefore represents that
of the complex between a2-macroglobulin and por-
cine pancreatic elastase in the presence of excess
protease inhibitor. This catalytic activity is only 70%
of the catalytic activity of the free enzyme (tab. 1).
Here we obtained a straight line with positive slope
(fig. 1). This confirms that a2-macroglobulin is prob-
ably responsible for the second part of the curve for
plasma (7), since this is the only known binder which
protects porcine pancreatic elastase from Inhibition
by arprotease inhibitor.
To investigate the phenomenon further we titrated
various mixtures of arprotease inhibitor and a2-ma-
croglobulin against fixed amounts of elastase. The
results are shown in figure 2. Using a constant
amount of elastase (267 pmol) with the various mix-
tures, the amount of residual catalytic activity was
related to the ratio of at-protease inhibitor to a2-
macroglobulin, s well s to the absolute amounts of
each. As the relative amount of arprotease inhibitor
was decreased, the equivalence volume (Ve) increased
from 4 μΐ to 44 μΐ, with a concurrent ten fold increase
in the absorbance at Ve. The curve depicted in figure l
for plasma is similar in shape to those of figure 2,
where the second half of the curve is not exactly
linear and becomes less linear s the amount of a.r
10 20 30 40 50 60 70 80 90 100 110 120 130
r Protease inhifoitor/ ocz-mocroglobulin mixture [μΐ]
Fig. 2. Titration of different mixtures of arprotease inhibitor
and a2-raacroglobulin against 267 pmol of elastase. The



























protease inhibitor is reduced. This is beca se the
Inhibition by cti-protease inhibitor is lower and a2-
macroglobulin becomes more prominent. Hence the
competition between the two is more obvious. This
is added to the constraint that f2 is smaller than fl5
and the value of the factor varies s the amount of
di-protease inhibitor increases (see below). Further-
more, the maximum catalytic activity of the complex
in the presence of excess arprotease inhibitor cannot
exceed 0.7 times the catalytic activity of the uiicom-
plexed enzyme.
Although pure samples of arprotease inhibitor and
<x2-macroglobulin gave linear regressions when ti-
trated separately, detennination of a2-macroglobulin
in a mixture of arprotease inhibitor and a2-macroglo-
bulin produced a non-linear curve (fig. 3). Hence in
devising a inethod for determining a2-macroglobulin
in a mixture containing both inhibitors, this non-
linearity must be taken into account. In the suggested
assay we use 10 μ! of plasma. This corresponds to
the initial practically linear portion of the curve.
As a result of the above experiments certain modificar
tions were made of the methods described above, in
order to determine a2-macrogl bulin and arprotease
inhibitor functional activities in plasma.
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Fig. 3. Titration of a mixture of arprotease inhibitor (7.5
μπιοΙ/1) and a2-macroglobulin (2.3 μιηοΐ/ΐ) against 267
picomol of elastase. The catalytic activity was measured
after neutralization of unbound elastase with 570 pmol
of arprotease inhibitor (See Methods).
j Since the initial region of the curve in figure 3 is
practically linear we can make this approximation
with only a small error. Over the linear region
Dv = 2K · B · V · f2 · t3,
where
Dv is the absorbance measured
V is the volume of plasma added
t3 is the incubation time.
Hence, provided we use a sufficiently low volume of
plasma we can expect good results for the determina-
tion of a2-macroglobulin.
D0 = K · c · t2 K is pH dependent.
D0 is absorbance with np plasma added.
Dv = 2 B · V · f2 t3 - D0/c · t2
B = Dv
2 - D o : V - t 3 - f 2
Substituting know val es in this equation
DioB = χ 15.2 [μmol/l]
D4o
of citric acid solution (100 g/l). D0 is the absorbance
at 410 nm developed in two minutes under these
conditions. A blank is determined by adding the citric
acid solution before the addition of Substrate.
Determination of a2-macroglobulin functional activity
in plasma
In order to avoid the necessity of diluting the plasma
we suggest an increased amount of porcine pancreatic
elastase be used in contrast to that used in figure 1.
For most normal plasma 1.6 nmol per assay is satis-
factorjf, giving an equivalence volume of about 40 μΐ
of plasma in 3.2 ml of Tris-HCl buffer (0.1 mol/1) pH
7.4 at 37 °C for 10 min. The excess elastase is then
reacted with an excess of <xrprotease inhibitor
(4 nmol) for a further 15 min at 37 °C. The residual
catalytic activity, D10, for the 10 μΐ serum is deter-
mined by using succinyl-trialanyl-p-nitroanilide (2000
μg per assay), and incubating for 15 min (t3) at 37 °C.
Determination of. functional activity of arprotease in-
hibitor in plasma
Except for patients in an acute phase, where the aj-
protease inhibitor could rise to very high levels, we
have found that satisfactory results are obtained with
20 μΐ of plasma and 1.6 nmol of porcine pancreatic
elastase (100 μg of the 40% pure product) in 2.3 ml
of Tris-buffer (0.1 mol/1 at pH 7.4). The two reactants
are kept at 37 °C for 5 min. Then 50 μΐ of a solution
of enzyme Substrate (40 g/J) is added and colour
generation allowed to proceed for a further 5 min.
The enzyme reaction is stopped by adding 0.5 ml of
citric acid solution (100 g/l). Absorbance is read at
410 nm. A zero time blank is determined by adding
the citric acid before adding the Substrate in a dupli-
cate assay.
Substituting known val es in the equation for A:
Do [g/l],
A = 80 - 32 χ D2o - 0.52 B [mol/1]
where DIO is value pf Dv for V = 10 μΐ plasma.
Determination of DQ
Using 1.6 nmol (100 μg of 40% pure) of porcine
pancreatic elastase per assay the absorbance devel-
oped in 3.2 ml of buffer at 37 °C with 50 μΐ of
suc nyl-tnalanyl-/?-nitroanilide (2000 μg per assay)
is measured. The colour development is only linear
for about 3 min under these conditions, hence t2 is
taken s 2 min. The reaction is stopped with 0.5 ml
80 - 32 χ D20
Do
- 5.9 χDioΊΟΓ [mol/1]
Determination of equivalence point
The volume of plasma used for the above assay must
not exceed Ve. Hence it is useful to know this value.
At the equivalence point c = a + 2b
= Vc (A + 2B)
Ve = c/(A + 2B)
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Hence we can calculate the Total Elastase Inhibiting
Capacity (TEIC) which is defined s the number of
ml of plasma required to bind l μπιοί of porcine
pancreatic elastase.
TEIC = Vc χ 0.625 ml in our assay.
:As pointed out by Meyer et al. (7) the enzymatic
'determination of arprotease inhibitor is more specific
:and much more rapid than immunological proce-
'dures. The ability to determine the functional activi-
ties of both arprotease inhibitor and a2-macroglobu-
ilin in the same specimen could be of importanee in
the study of degenerative lung diseases.
A study of patients suffering from emphyserna has
ishown that functional actiyity leVels of a2-macrogl -
bulin in these patients are significaritly higher than
.those in healthy persons. This datarwill be published
elsewhere.
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